Survey of Ophthalmology
Volume 49, Issue 2 , Pages 197-213 , March 2004

Determinants of eye drop size

  • Luc Van Santvliet, PhD
    • ,
  • Annick Ludwig, PhD

      Affiliations

    • Corresponding Author InformationReprint address: Prof. Dr. Annick Ludwig, University of Antwerp (U.I.A.), Laboratory of Pharmaceutical Technology and Biopharmacy, Universiteitsplein 1, 2610 Antwerpen, Belgium.

References 

  1. Adler A, McElwain G, Merli G, Martin J. Systemic effects of eye drops. Arch Intern Med. 1982;142:2293–2294
  2. Armour D: Dropper plug. US Patent 2 987 223, 1961
  3. Arnaud Y, Dauphin A, Mignot A. Interactions matières plastiques—medicaments. In:  Postaire E editors. Les matières plastiques, à usage pharmaceutique et medico-chirurgical, tome I. Paris: Editions Médicales Internationales; 1986;p. 121–172
  4. Ball S, Schneider E. Cost of beta-adrenergic receptor blocking agents for ocular hypertension. Arch Ophthalmol. 1992;110:654–657
  5. Barbeau D. Scientifically speaking. Addressing the therapeutic needs of the elderly. Control Rel Newsl. 1997;14:6–9
  6. Beebe D, Denton D, Radwin R, Webster J. A silicon-based tactile sensor for finger-mounted applications. IEEE Trans Biomed Eng. 1998;45:151–159
  7. Bendtsen L, Jensen R, Jensen N, Olesen J. Muscle palpation with controlled finger pressure : new equipment for the study of tender myofascial tissues. Pain. 1994;59:235–239
  8. Beyrich T. Notiz zur Beurteillung der Eindrückbarkeit von Plastikaugentropfenflaschen. Pharmazie. 1976;31:577
  9. Blaug S, Canada A. Relationship of viscosity, contact time and prolongation of action of methylcellulose containing ophthalmic solutions. Am J Hosp Pharm. 1965;22:662–666
  10. Bonnelye J, Chatelier J, Grégoire J: Embout goutte-à-goutte pour flacon, et flacon équipé d'un tel embout. Fr Patent 2 696 997, 1992
  11. Bourny E, Dumolard L, Peronnet A. Remplissage intégré aseptique : la technologie blow-fill-seal (BFS) dans 'industrie pharmaceutique. STP Pharma Pratiques. 1995;3:203–214
  12. British Pharmaceutical Code 1973. London: The Pharmaceutical Press; 1973;
  13. Brown J, Hotchkiss M, Davis B. Creating smaller eyedrops by reducing eyedropper tip dimensions. Am J Ophthalmol. 1985;99:460–464
  14. Brown R, Lynch M. Design of eyedropper tips for topical beta-blocking agents. Am J Ophthalmol. 1986;102:123–124
  15. Bunin L: Bottle for controllably dispensing a liquid by drops. Eur Patent 0 362 911 A1, 1988
  16. Burns E, Mulley G. Practical problems with eye drops among elderly ophthalmology outpatients. Age Ageing. 1992;21:168–170
  17. Busche S, Gramer E. Verbesserung der Augentropfenapplikation und Compliance bei Glaukompatienten. Klin Monatsbl Augenheilkd. 1997;211:257–262
  18. Carter S. Cooper and Gunn's Dispensing for Pharmaceutical Students. Kent, UK: Pitman Medical; 1975; pp 641–5
  19. Chau N, Pétry D, Bourgkard E, et al.  Comparison between estimates of hand volume and hand strengths with sex and age with and without antropometric data in healthy working people. Eur J Epidemiol. 1997;13:309–316
  20. Chrai S, Makoid M, Eriksen S, Robinson J. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63:333–338
  21. Corlett A. Aids to compliance with medication. Br Med J. 1996;313:926–929
  22. Diamond J. Systemic adverse effects of topical ophthalmic agents. Implications for older patiens. Drugs Aging. 1997;11:352–360
  23. Diggory P, Franks W. Medical treatment of glaucoma—a reappraisal of the risks. Br J Ophthalmol. 1996;80:85–89
  24. Dispomed Ltd: Device for assisting dispensing. GB Patent 2 216 802 A, 1989
  25. Dudinski O, Finnin B, Reed B. Acceptability of thickened eye drops to human subjects. Curr Ther Res. 1983;33:322–338
  26. European Pharmacopoeia. Strassburg, Council of Europe, 2002, ed 4
  27. File R, Patton T. Topically applied pilocarpine, human pupillary response as a function of drop size. Arch Ophthalmol. 1980;98:112–115
  28. Fiscella R. Costs of glaucoma medications. Am J Health Syst Pharm. 1998;55:272–275
  29. Flach A. Systemic toxicity associated with topical ophthalmic medications. J Fla Med Assoc. 1994;81:256–260
  30. Frangie J. Clinical pharmacokinetics of various topical ophthalmic delivery systems. Clin Pharmacokinet. 1995;29:130–138
  31. Fraunfelder F, Meyer M. Systemic side effects from ophthalmic timolol and their prevention. J Ocul Pharmacol. 1987;3:177–184
  32. Fraunfelder F, Meyer S. Systemic adverse reactions to glaucoma medications. Int Ophthalmol Clin. 1989;29:143–146
  33. Glynn R, Seddon J, Krug J, et al.  Falls in elderly patients with glaucoma. Arch Ophthalmol. 1991;109:205–210
  34. Heinlein H: Pipettiervorrichtung für Flaschen. Offenlegungsschrift 29 01 827, 1980
  35. Holdsworth D, Roberts M, Polack A. Fate of chlorbutol during storage in polyethylene dropper containers and simulated patient use. J Clin Hosp Pharm. 1984;9:29–39
  36. Hook W, Stanley J. Assessment of thumb to index pulp to pulp pinch grip strengths. J Hand Surg. 1986;11B:91–92
  37. Hugues F, Le Jeune C. Systemic and local tolerability of ophthalmic drug formulations. Drug Saf. 1993;8:365–380
  38. Järvinen K, Järvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Del Rev. 1995;16:3–19
  39. Jenkins W, Osborn K. Packaging drugs and pharmaceuticals. Basel: Technomic Publishing Co; 1993;
  40. Jensen C: Eye drop alignment glasses. US Patent 5 255 024, 1993
  41. Jensen T, Radwin R, Webster J. A conductive polymer sensor for measuring external finger forces. J Biomech. 1991;24:851–858
  42. Jho C, Burk R. Drop weight technique for the measurement of dynamic surface tension. J Colloid Sur Sci. 1983;95:61–71
  43. Jho C, Carreras M. The effect of viscosity on the drop weight technique for the measurement of dynamic surface tension. J Colloid Interface Sci. 1984;99:543–548
  44. Kass M, Gordon M, Meltzer D. Can ophthalmologists identify patients defaulting from pilocarpine therapy?. Am J Ophthalmol. 1986;101:524–530
  45. Kass M, Meltzer D, Gordon M. A miniature compliance monitor for eyedrop medication. Arch Ophthalmol. 1984;102:1550–1554
  46. Koe M. Drop size of ocular timolol solutions. Am J Health Syst Pharm. 1995;52:2469
  47. Kooner K, Zimmerman T. A glaucoma time-table card. Ann Ophthalmol. 1986;19:43–44
  48. Lahdes K, Huupponen R, Kaila T, et al.  Systemic absorption of ocular scopolamine in patients. J Ocul Pharmacol. 1990;6:61–66
  49. Lalueza Broto M, Montoro Ronsano J, Cano Marrón S, et al.  Determinatión del tamaño de gota en colirios de timolol. Farm Clin. 1989;6:144–150
  50. Lang J. Ocular drug delivery conventional ocular formulations. Adv Drug Del Rev. 1995;16:39–43
  51. Lederer C, Harold R. Drop size of commercial glaucoma medications. Am J Ophthalmol. 1986;101:691–694
  52. Lee V. Precorneal, corneal, and postcorneal factors. In:  Mitra A editors. Ophthalmic drug delivery systems. Basel: Marcel Dekker; 1993;p. 59–81
  53. Lee V, Robinson J. Review: Topical ocular drug delivery, recent developments and future challenges. J Ocul Pharmacol. 1986;2:67–108
  54. Lee Y, Simomora P, Pinsuwan S, Yalkowsky H. Review on the systemic delivery of insulin via the ocular route. Int J Pharm. 2002;233:1–18
  55. Letocha C. Methods for self-administration of eyedrops. Ann Ophthalmol. 1985;17:768–769
  56. Loeffler M, Hornblass A. Hazards of unit dose artificial tear preparations. Arch Ophthalmol. 1990;108:639–640
  57. Loewenstein A, Bolocinic S, Goldstein M, Lazar M. Application of eye drops to the medial canthus. Graefe's Arch Clin Exp Ophthalmol. 1994;232:680–682
  58. Ludwig A, Van Ooteghem M. Influence of the surface tension of eye drops on the retention of a tracer in the precorneal area of human eyes. J Pharm Belg. 1988;43:157–162
  59. Lynch M, Brown R, Goode S, et al.  Reduction of phenylephrine drop size in infants achieves equal dilatation with decreased systemic absorption. Arch Ophthalmol. 1987;105:1364–1365
  60. Marquardt N. Validation of Form-Fill-Seal. Pharm Ind. 1995;57:681–686
  61. Maruo S. The study of the pinching power. J Jpn Orthop Assn. 1979;52:979–988
  62. Mazuel C, Chalmin P: A dropper tip for dispensing a liquid, in particular eye drops. Eur. Patent 0 431 885 A1, 1989
  63. McDonald F, Parkin J. The effect of disoidum edetate and sodium chloride on the stability of ethylmercury arising fro the decomposition of thimerosal (thiomersal). Drug Dev Ind Pharm. 1995;21:2403–2410
  64. Meier A, Hager H, Munzel K. Die dosierung von Flüssigkeiten mit Tropfgeräten. Pharm Acta Helv. 1956;31:177–254
  65. Mishima S, Gasset A, Klyce S, Baum J. Determination of tear volume and tear flow. Inv Ophthalmol. 1966;5:264–276
  66. Montoro J, Lalueza P, Cano S, et al.  Drop size and systemic adverse effects in timolol ophthalmic solution. DICP Ann Pharmacother. 1990;24:439–440
  67. Morlet N, Kelly M. Improving drop administration by patients. J Ophthalmic Nurs Technol. 1996;15:60–64
  68. Morlet N, Morlet G. A method of drop administration. Ophthalmic Surg Lasers. 1997;28:687–689
  69. Morrow D, Leirer V, Sheikh J. Adherence and medication instructions. Review and recommendations. J Am Geriatr Soc. 1988;36:1147–1160
  70. Munroe W, Rindone J, Kershner R. Systemic side effects associated with the ophthalmic administration of timolol. Drug Intell Clin Pharm. 1985;19:85–89
  71. Nelson J. Corneal abrasion resulting from a unit dose artificial tear dispenser. Am J Ophthalmol. 1987;103:333–334
  72. Nordenskiöld U. Daily activities in women with rheumatoid arthritis. Scand J Rehabil Med. 1997;37(Suppl):1–72
  73. O'Donoghue E. Beta blockers and the elderly with glaucoma: are we adding insult to injury?. Br J Ophthalmol. 1995;79:794–796
  74. Olejnik O. Conventional systems in ophthalmic drug delivery. In:  Mitra A editors. Ophthalmic Drug Delivery Systems. Basel: Marcel Dekker; 1993;p. 177–198
  75. O'Sullivan E, Malhotra R, Migdal C. Prescription of eye drops. Postgrad Med J. 2001;77:654–655
  76. Palmer E. How safe are ocular drugs in pediatrics?. Ophthalmology. 1986;93:1038–1040
  77. Partilla T, Skinner F, Dolder R. Behälter für flüssige Augenarzneien. In:  Dolder R,  Skinner F editor. Ophthalmica, Band I Pharmazeutische Grundlagen ihrer Zubereitung. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1990;p. 576–591
  78. Patton F, Robinson R. Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes. J Pharm Sci. 1976;65:1295–1301
  79. Patton T. Pharmacokinetic evidence for improved ophthalmic drug delivery by reduction of instilled volume. J Pharm Sci. 1977;66:1058–1059
  80. Patton T. Ocular drug disposition. In:  Robinson J editors. Ophthalmic Drug Delivery Systems. Washington DC: American Pharmaceutical Association; 1980;p. 27–53
  81. Petursson G, Cole R, Hanna C. Treatment of glaucoma using mini-drops of clonidine. Arch Ophthalmol. 1984;102:1180–1181
  82. Prince D, Carliner N. Respiratory arrest following first dose of timolol ophthalmic solution. Chest. 1983;85:640–641
  83. Quigley H. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389–393
  84. Rivers P. Compliance aids—so they work?. Drugs Aging. 1992;2:103–111
  85. Rosenthal A, Zimmerman J, Tanner J. Educating the glaucoma patient. Br J Ophthalmol. 1983;67:814–817
  86. Salminen L. Review: Systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol. 1990;6:243–249
  87. Schwartz J, Christensen R, Lee D. Comparison of timolol maleate and levobunolol: doses and volume per bottle. Arch Ophthalmol. 1989;107:17–18
  88. Shaw D: Improvements in droppers for pharmaceutical liquids. GB Patent 1 169 255, 1969
  89. Shell J. Ophthalmic drug delivery systems. Surv Ophthalmol. 1984;29: 1779–28
  90. Shell J. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982;26:207–218
  91. Sinclair C, Tallentire A. Performance of Blow/Fill/Seal equipement under contolled airborne microbial challenges. PDA J Pharm Sci Techn. 1995;49:294–299
  92. Smith J. The need of ophthalmic patients for a compliance aid. Pharm J. 1992;247:721–722
  93. Smith S. Eyedrop instillation for reluctant children. Br J Ophthalmol. 1991;75:480–481
  94. Sorab J, Alle R, Gonik B. Tactile sensory monitoring of clinician-applied forces during delivery of newborns. IEEE Trans Biomed Eng. 1988;35:1090–1093
  95. Sorensen S, Abel S. Drop size of ocular carteolol hydrochloride. Am J Hosp Pharm. 1994;51:1470–1473
  96. Stevens J, Matheson M. Survey of the contamination of eyedrops of hospital inpatients and recommendatios for the changing of current practice in eyedrop dispensing. Br J Ophthalmol. 1992;76:36–38
  97. Stewart W, Sine C, Cate E, et al.  Daily cost of β-adrenergic blocker therapy. Arch Ophthalmol. 1997;115:853–856
  98. United States Pharmacopeia. National Formulary. USP XXIV NF XIX. Rockville, MD: United States Pharmacopeial Convention Inc; 1999;
  99. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol. 1993;37:435–456
  100. Van Horssen N, Cox H. Verpakkingen, in Bolhuis G, Cox H, Zuidema J (eds): Receptuurkunde, Bereiden, keuren en afleveren van geneesmiddelen in de apotheek's Gravenhage, Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, 1995, pp 152–205
  101. Van Ooteghem M. Augenpräparate. In:  Nürnberg E,  Surmann P editor. Hagers Handbuch der pharmazeutischen Praxis Band 2 Methoden. Berlin: Springer-Verlag; 1991;p. 633–637
  102. Van Ooteghem M, Ludwig A. Study on parameters influencing the drop volume of solutions from flexible dropper bottles. Abstract Proc 12th Pharm Techn Conf. 1993;2:612–622
  103. Van Santvliet L, Caljon K, Pieters L, Ludwig A. Physicochemical properties, NMR spectroscopy and tolerance of inclusion complexes of antazoline and tetracaine with hydroxypropyl-beta-cyclodextrin. Int J Pharm. 1998;171:147–156
  104. Van Santvliet L, Ludwig A. Influence of the dropper tip design on the size of eye-drops. Pharm Ind. 2001;63:402–409
  105. Van Santvliet L, Ludwig A. Influence of the physico-chemical properties of ophthalmic viscolysers on the weight of drops dispensed from a flexible dropper bottle. Eur J Pharm Sci. 1999;7:339–345
  106. Van Santvliet L, Ludwig A. Dispensing eye drops from flexible plastic dropper bottles (Part I: Influence of the packaging characteristics). Pharm Ind. 1999;61:92–96
  107. Van Santvliet L, Ludwig A. Dispensing eye drops from flexible plastic dropper bottles (Part II: Influence of the physico-chemical properties of the formulation and the manipulation technique by the patient). Pharm Ind. 1999;61:194–198
  108. Van Santvliet L, Ludwig A. Dispensing eye drops from flexible plastic dropper bottles (Part III: Comparison between volunteers and healthy patients). Pharm Ind. 1999;61:276–280
  109. Van Santvliet L, Ludwig A. The influence of penetration enhancers on the volume instilled of eye drops. Eur J Pharm Biopharm. 1998;45:189–198
  110. Van Santvliet L, Sam T, Ludwig A. Packaging of ophthalmic solutions—Influence on stability, sterility, eye drop instillation and patient compliance. Eur J Pharm Biopharm. 1996;42:375–384
  111. Vocci M, Robin A, Wahl J, et al.  Reformulation and drop size of apraclonidine hydrochloride. Am J Ophthalmol. 1992;113:154–160
  112. Webster J. Tactile sensors for robotics and medicine. New York: Wiley; 1988;
  113. Weiss M, Hendrickson J. Information on drop size needs to be eyed closely. Am J Hosp Pharm. 1994;51:2969–2970
  114. Whitson J, Love R, Brown R, et al.  The effect of reduced eyedrop size and eyelid closure on the therapeutic index of phenylephrine. Am J Ophthalmol. 1993;115:357–359
  115. Winfield A, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74:477–480
  116. Wisher S. An assistive eye-drop mold. Am J Occup Ther. 1991;45:751–752
  117. Zimmerman T, Zalta A. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol. 1983;28:252–257

☆ The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

PII: S0039-6257(03)00183-8

doi: 10.1016/j.survophthal.2003.12.009

Survey of Ophthalmology
Volume 49, Issue 2 , Pages 197-213 , March 2004

Article Tools

* Image Usage & Resolution